振源胶囊联合环磷腺苷治疗冠心病慢性心力衰竭的临床研究

目的探索振源胶囊联合环磷腺苷治疗冠心病慢性心力衰竭的治疗效果。方法选取2014年2月—2017年6月于山阳县人民医院和西安交通大学第一附属医院接受治疗的冠心病慢性心力衰竭患者284例,随机分为对照组和治疗组,每组各142例。对照组患者静脉注射注射用环磷腺苷,35 mg加入5%葡萄糖注射液250 m L,1次/d。治疗组患者在对照组的基础上饭后口服振源胶囊,2粒/次,3次/d。两组患者均治疗30 d。评价两组患者临床疗效,同时比较治疗前后两组患者临床指标、心功能改善情况和不良反应情况。结果治疗后,对照组和治疗组总有效率分别为89.44%、98.59%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者脑钠肽(BNP)和C反应蛋白(CRP)水平均明显降低,6 min步行距离明显增加,同组比较差异具有统计学意义(P0.05);且治疗组患者临床指标改善情况明显优于对照组(P0.05)。治疗后,两组患者左室射血分数(LVEF)明显升高,左室收缩末期内径(LVESD)和左室舒张末期内径(LVEDD)明显降低,同组比较差异具有统计学意义(P0.05);且治疗组患者心功能改善情况明显优于对照组(P0.05)。治疗过程中,治疗组患者的不良反应例数明显少于对照组的,两组比较差异具有统计学意义(P0.05)。结论振源胶囊联合环磷腺苷治疗冠心病慢性心力衰竭患者疗效显著,能够有效改善患者心功能,具有一定的临床推广应用价值。

Clinical study of Zhenyuan Capsules combined with adenosine monophosphate in treatment of chronic heart failure of coronary heart disease

Objective To explore the therapeutic effect of Zhenyuan Capsules combined with adenosine monophosphate in treatment of chronic heart failure of coronary heart disease. Methods Patients (284 cases) with chronic heart failure of coronary heart disease in Shanyang County People''s Hospital and the First Affiliated Hospital of Xi''an Jiaotong University from February 2014 to June 2017 were randomly divided into control and treatment groups, and each group had 142 cases. Patients in the control group were iv administered with Adenosine Cyclophosphate for injection, 35 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Zhenyuan Capsules on the basis of the control group after meals, 2 grains/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the clinical indicators, the improvement of cardiac function and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 89.44% and 98.59%, respectively, and there were differences between two groups (P<0.05). After treatment, the BNP and CRP levels in two groups were significantly decreased, but 6 min walking distance was significantly increased, and there were differences in the same group (P<0.05). And the improvement of the clinical indicators in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the LVEF in two groups was significantly increased, but the LVEDD and LVESD were significantly decreased, and there were differences in the same group (P<0.05). And the improvement of cardiac function in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). During the treatment, patients occurred adverse reactions in the treatment were significantly less than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhenyuan Capsules combined with adenosine monophosphate has significant effect in treatment of chronic heart failure of coronary heart disease, can effectively improve the heart function, which has a certain clinical application value.